Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease

The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 5, May 2021, Pages 1325–1332, https://doi.org/10.1210/clinem/dgab070

Published: 09 February 2021




The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD).


Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature

Matteo Spaziani, Chiara Tarantino, Natascia Tahani, Daniele Gianfrilli, Emilia Sbardella, Andrea M Isidori, Andrea Lenzi, Antonio F Radicioni

Frontiers in Endocrinology 2021, 12: 634288

doi: 10.3389/fendo.2021.634288